Profile
Robert Ho worked as a Senior Finance Director at DaVita, Inc. and as a Vice President-Investment Banking Division at Morgan Stanley & Co. LLC.
He also served as the Secretary, Chief Financial & Accounting Officer at Neoleukin Therapeutics, Inc. and as the Chief Financial Officer & Treasurer at Third Harmonic Bio, Inc. Mr. Ho received his undergraduate degree from the University of Notre Dame and his MBA from the University of Virginia Darden School of Business.
Former positions of Robert Ho
| Companies | Position | End |
|---|---|---|
| THIRD HARMONIC BIO, INC. | Director of Finance/CFO | 09/11/2023 |
| NEUROGENE INC. | Director of Finance/CFO | 28/02/2022 |
| DAVITA INC. | Director of Finance/CFO | - |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Corporate Officer/Principal | - |
Training of Robert Ho
| University of Notre Dame | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| DAVITA INC. | Health Services |
| THIRD HARMONIC BIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
- Stock Market
- Insiders
- Robert Ho
